Genomma Lab InternacionalB de CV's EBIT per Share for the
three
months ended in Mar. 2026 was MXN0.84.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN3.21.
During the past 12 months, the average EBIT per Share Growth Rate of Genomma Lab InternacionalB de CV was -8.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's EBIT per Share or its related term are showing as below:
MEX:LABB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -58.9 Med: 6.7 Max: 126.2
Current: 4.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Genomma Lab InternacionalB de CV was 126.20% per year. The lowest was -58.90% per year. And the median was 6.70% per year.
MEX:LABB's 3-Year EBIT Growth Rate is ranked worse than 55.01% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.6
vs MEX:LABB: 4.90
Genomma Lab InternacionalB de CV (MEX:LABB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Genomma Lab InternacionalB de CV EBIT per Share Related Terms
Genomma Lab InternacionalB de CV EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a EBIT per Share of MXN3.21 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genomma Lab InternacionalB de CV and its competitors. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #445 out of 809 companies in the Drug Manufacturers industry, placing it in the top 55%.
Is Genomma Lab InternacionalB de CV's EBIT per Share too high?
Genomma Lab InternacionalB de CV's current EBIT per Share is MXN3.21. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #445 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #445 out of 809 companies for EBIT per Share. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median EBIT per Share is 7.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.60, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current EBIT per Share is MXN3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current EBIT per Share is MXN3.21. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current EBIT per Share is MXN3.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
EBIT per Share: MXN3.21
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
